Skip to Main Content

Editorial Board

Editor-in-Chief: Professor Wanjin Hong

Affiliation:

Biography:

Associate Editors

Edward Bolt

Affiliation: University of Nottingham, UK

Biography: Edward’s lab is located in the medical school of QMC, University of Nottingham, where they research DNA repair and CRISPR-Cas immunity. Prior to his current position, Ed was a PI as a Wellcome Trust funded Research Career Development Fellow, also at Nottingham, after 5 years as a post-doc working on bacterial DNA repair. His PhD was at the University of London (UCL and QMUL) researching the enzymology of a key step in tetrapyrrole biosynthesis. He has strong collaborative links with several research establishments and universities internationally that allows his laboratory to combine genetics, biochemistry and structural analyses of DNA repair and CRISPR-Cas immunity. 

Kakoli Bose

Affiliation: Tata Memorial Centre, India

Biography: Programmed cell death or apoptosis poses an important impediment against cancer.  It is evident that effective treatment of cancer needs innovative identification of novel targets from the apoptotic pathway and their therapeutic intervention with greater efficacy and lower toxicity. Dr. Bose’s laboratory is committed toward this objective with her research interest being identification and characterization of targets in the apoptotic pathway so as to design modulators/analogs with desired characteristics using multidisciplinary approach. The group works on the high temperature requirement family of serine proteases (HtrA), the interaction between anti apoptotic c-FLIP and calmodulin as well as caspase-8 and FADD of extrinsic cell death pathway, and the Bcl2 family proteins and their interacting partners. Moreover, the group is now entering into application-based translation research that includes enzymes involved in metabolic reprogramming and their role in altering cancer signaling pathways.


Anderly Chueh

Affiliation: The University of Melbourne, Australia

Biography: Dr Chüeh completed his undergraduate studies at The University of Melbourne majoring in Biochemistry and Genetics and PhD studies in Human Genetics at the Murdoch Children’s Research Institute (MCRI) where he performed pioneering research in the epigenetic regulation of centromere structure and function. In 2008 he joined the Ludwig Institute of Cancer Research (LICR) were he identified a novel clinically relevant transcriptional axis that is predictive of HDAC inhibitor drug sensitivity in tumour cells from multiple cancer types. Dr Chüeh was recruited to The Walter and Eliza Hall Institute (WEHI) in 2014 where lead target identification and MoA studies on first-in-class small molecule antimitotics that has demonstrated in vivo activities and licensed to commercial partners for co-development. Since 2016, Dr Chüeh has worked as a Senior Scientist contributing to high throughput screening, biomarker identification and target validation to multiple drug discovery pipelines in a leading Australian biotech company (Cancer Therapeutics CRC) that has successfully licensed novel small molecules to multinational pharmaceutical companies such as Merck and Pfizer. Dr Chüeh is an Associate Editor for UK Biochemical Society’s Biosciences Reports journal. He has published over 22 research articles in top-tier international cancer research and human genetics journals and won numerous awards.   


Christopher Cooper

Affiliation: University of Huddersfield, UK

Biography: Following my first degree in Biochemistry at the University of Oxford (Merton College), I moved to the Department of Engineering Science and Linacre College to pursue a PhD/DPhil in molecular microbiology and biochemistry. During this time I developed an interest in DNA replication and repair, studying thermoacidophilic archaea and their DNA polymerases. To pursue my interests in genomics, I then undertook a Masters degree in Bioinformatics at the University of York with a research placement at the University of Uppsala in Sweden. I subsequently moved into eukaryotic molecular biology, working for 3 years at the Nuffield Department of Clinical Laboratory Sciences in Oxford. Here I researched microRNA and cancer-testis antigen expression profiles in human lymphomas, cementing my interests in cancer research. I then undertook two postdoctoral positions at the Structural Genomics Consortium (Oxford), working on high-throughput crystallography and biochemistry of human DNA polymerases and helicases involved in genome integrity, SNF2 family members in chromatin remodelling and ETS transcription factors. I continued to research genome integrity factors in cancer during a short postdoc at the Sir William Dunn School of Pathology (Oxford), using structural, biochemical and cell biology approaches to study endonucleases and chromatin remodeling SNF2 ATPases involved in the DNA damage response. During my latter postdoc positions I was appointed as an E.P. Abraham Cephalosporin Junior Research Fellow and a member of the Governing Body at Linacre College, and also as a College Lecturer in Biochemistry at the Queen’s College. I joined the University of Huddersfield as a Senior Lecturer in Biological Sciences in 2015.


Amanda Coutts

Affiliation: Nottingham Trent University, UK

Biography: To be provided


Jean-Bernard Denault

Affiliation: Université de Sherbrooke, Canada

Biography: Jean-Bernard Denault is a professor at the Université de Sherbrooke, Québec, Canada, with a Ph.D. degree in Pharmacology. His research interests cover the mechanisms of regulation, activation, and activity of proteolytic enzymes, more specifically that of caspases during apoptosis. Dr. Denault's laboratory is interested in caspase biology with emphasis on their roles in cancer. His projects take advantage of protein engineering, enzymological characterization, gene manipulation, cancer cell models, structural biology, and other approaches to understand how caspases work and how these results can potentially lead to the development of new strategies to modulate their activity.


Claire Friel

Affiliation: University of Nottingham, UK

Biography: To be provided


Nicola K. Gray

Affiliation: University of Edinburgh, UK

Biography: To be provided

Weiping Han

Affiliation: Agency for Science, Technology and Research, A*Star Institute, Singapore

Biography: Weiping Han obtained his Ph.D. in Physiology from Cornell University, and did his postdoctoral work at the University of Pittsburgh and HHMI/UT Southwestern Medical Center in Dallas. In 2005, he moved to Singapore to set up a research program in the Laboratory of Metabolic Medicine (LMM) at Singapore Bioimaging Consortium (SBIC), and was promoted to Research Director / Professor in 2013. Currently he is Deputy Director of SBIC with concurrent appointment as Head of LMM. He is also Research Director at Institute of Molecular and Cell Biology; Professor in the Department of Biochemistry at National University of Singapore and Program in Cardiovascular and Metabolic Disorders, Duke-NUS Medical School. His research interest is on the biological basis of metabolic diseases and associated complications.


W. Eustace Johnson

Affiliation: University of Chester, UK

Biography: To be provided


Zaklina Kovacevic

Affiliation: University of Sydney, Australia

Biography: Dr. Kovacevic is a Senior Research Fellow in the Department of Pathology at the University of Sydney, where she leads the NDRG1 and Metastasis Research Group. Her team consists of 3 PhD students and a post-doctoral fellow. She holds 2 externally funded fellowships, including the NHMRC R.D. Wright Career Development Fellowship and the CINSW Career Development Fellowship. Her research focuses on understanding metastasis, identifying molecular markers that control this process and developing novel treatment strategies designed to inhibit metastatic progression. Throughout her career, she has published 71 journal articles/books in high quality international journals (31 as 1st/senior/co-senior author). Her achievements were recognized by a suite of awards and prizes, including Cancer Institute of NSW Premier’s Award for Outstanding Cancer Research Fellow of the Year 2016, Sydney Medical School Award for Excellence for Outstanding Early Career Researcher (2016), Rebecca L. Cooper Medal, Peter Bancroft Prize and invitations to present her work at 48 conferences.


Wei Li

Affiliation: Beijing Children's Hospital, China

Biography: To be provided


Frank Michelangeli

Affiliation: University of Chester, UK

Biography: To be provided


Amy L. Milton

Affiliation: University of Cambridge, UK

Biography: To be provided


Nathan Subramaniam

Affiliation: Queensland University of Technology, Brisbane, Australia

Biography: Professor Nathan Subramaniam received his PhD from Purdue University, W. Lafayette, Indiana, USA. He did his postgraduate research at the Department of Biochemistry, University of California at Davis, USA. He then joined the group of Prof Wanjin Hong at the Institute of Molecular and Cell Biology, Singapore, where he completed his postdoctoral training in cell biology and protein trafficking. He is currently Professor in Biomedical Sciences (Molecular Medicine) at the Queensland University of Technology, Brisbane, Australia, and leads the Liver Disease and Iron Disorders Research Group at the Institute of Health and Biomedical Innovation and School of Biomedical Sciences. Professor Subramaniam’s interests lie in the study of liver disease and how the liver regulates iron homeostasis. His research interests include understanding the genetics of iron disorders, cell biology of iron transporters, functional consequences of disease-causing mutations, mechanisms involved in regulating iron homeostasis and the development of liver injury.


Yee-Joo Tan

Affiliation: National University of Singapore, Singapore

Biography: To be provided


Alexey Teplyakov

Affiliation: Hauptman-Woodward Medical Research Institute, USA

Biography: To be provided


Vinay Tergaonkar

Affiliation: Institute of Molecular and Cell Biology, A*Star Institute, Singapore

Biography: Vinay Tergaonkar obtained his Ph.D. (2001) through an international cancer society (UICC) fellowship for collaborative research at Tufts University, Boston, USA. He has been a fellow (2001-2004) and a special fellow (2004-present) of the Leukemia and Lymphoma Society of America and conducted his postdoctoral studies at the Salk Institute for Biological Studies, La Jolla, California. He joined the Institute of Molecular and Cell Biology (IMCB), Singapore, in late 2005 as Principal Investigator and became a Senior Principal Investigator in 2010 and Research Director in 2015. He is also a Professor at School of Medicine at National University of Singapore. He serves on Editorial Boards of 1) Science Advances (AAAS), 2) Molecular and Cellular Biology (American Society for Molecular Biology), 3) Biochemical Journal (Portland Press) 4) Critical Reviews in Oncology/Hematology (Elsevier Press), 5) BMC Research Notes (Biomed Central) and 6) Telomeres and Telomerase. Work from his lab has received international recognition including the British council development award (2014), the Premiers’ fellowship from Government of South Australia (2015) and University of Macau Distinguished Professorship (2019).


Georg C. Terstappen

Affiliation: OxStem, Oxford, UK

Biography: Since September 2018 Georg C. Terstappen is CSO of OxStem in Oxford, UK. From March 2017 until April 2018 Georg was Head of Platform Technologies and Science China and Neurosciences TA Portfolio Leader at GSK’s R&D Centre in Shanghai. Georg was also Co-Chair of the Strategic Governing Group Neurodegeneration of the Innovative Medicines Initiative and Vice-Chair of its strategy group InnoMedS. From 2011-2016 he was Director of Discovery Biology at AbbVie and from 2002-2010 CSO of Siena Biotech - a neuroscience drug discovery company he co-initiated. Georg has 25 years of experience in drug discovery, is an inventor/co-inventor of 14 patents and an author of more than 80 scientific publications. He previously worked at Bayer AG, GlaxoWellcome and GlaxoSmithKline and conducted research at the Max-Planck-Institute in Cologne and the Federal Research Centre Juelich for which he received his PhD in natural sciences in 1992.


David J. Timson

Affiliation: The University of Brighton, UK

Biography: David was born in Greater Manchester and studied biochemistry (BSc, PhD) at the University of Birmingham.  After post-doctoral work at the Universities of Oxford and Manchester, he became a lecturer in biochemistry at Queen’s University, Belfast.  He worked there for over 12 years, before leaving in 2015 to become Professor of Biochemistry and Head of the School of Pharmacy and Biomolecular Sciences at the University of Brighton.  His research interests are in protein biochemistry, particularly (i) how proteins “go wrong” in inherited metabolic diseases; (ii) studying metabolic enzymes and calcium binding proteins from parasitic worms as potential drug targets; (iii) investigating the enzymology of quinone oxidoreductases; (iv) altering the specificity of enzymes to exploit them as potential biocatalysts.


Mark D. Turner

Affiliation: Nottingham Trent University, UK

Biography: After completing his PhD in Medicine at the University of Liverpool, Dr Turner moved to the USA to undertake postdoctoral studies at The Scripps Research Institute, Harvard Medical School, and Albert Einstein College of Medicine. He then returned to the UK to take up a faculty appointment at Bart's and The London School of Medicine and Dentistry, before later moving to his current position at Nottingham Trent University.


Rietie Venter

Affiliation: University of South Australia, Australia

Biography: Rietie is currently the Head of Microbiology in the School of Pharmacy and Medical Sciences at the University of South Australia. Her research focuses on antimicrobial resistance in pathogenic microbes which is one of the most serious threats in healthcare today. Her group works on projects aimed at detecting antimicrobial resistance in clinical and environmental settings as well as understanding the factors that drive the rapid dissemination of antibiotic resistant organisms. She is also heading an antimicrobial drug discovery program aimed at finding new therapeutics against drug resistant pathogens.  Rietie obtained her BSc(Hons) and Master’s degrees with distinction from the University of the Free State in South Africa before securing a scholarship to do a PhD in the UK. After completing her PhD at the University of Leeds in the beautiful Yorkshire Dales, she moved to Cambridge, where she spent twelve years doing research on multidrug transporters, first as a post-doc and later running her own research group as a Royal Society Dorothy Hodgkin Fellow in the Department of Pharmacology. Not content with moving continents once in a lifetime, she left the ancient buildings and immaculate college lawns of Cambridge for sun and sea in Australia after sixteen years in the UK. 

Lam Kong Peng

Affiliation: A*Star Bioprocessing Technology Institute, Singapore

Biography: Professor Kong-Peng Lam is currently Executive Director of the Bioprocessing Technology Institute, Agency for Science Technology and Research (A*STAR) as well as Professor (with Tenure) at the National University of Singapore.  He is also Adjunct Professor at the School of Biological Sciences at Nanyang Technological University.  Dr Lam received his PhD training at Columbia University in the USA and did his postdoctoral training at the Institute for Genetics, University of Cologne in Germany where he worked on conditional gene knockout mouse models of diseases.  He is an immunologist by training and his research interests are in immune cell signalling, immunotherapy, host-pathogen interactions and biologics discovery and development. 


Ming Yang

Affiliation: Oklahoma State University, USA

Biography: Dr. Ming Yang is a plant cell and molecular biologist. His major contributions are in the areas of stomatal development, meiotic cell cycle progression, and cell morphogenesis in plants. He has investigated a number of Arabidopsis mutants that exhibit interesting phenotypes in the mentioned areas. His research emphasis is on detecting the effects of individual and combined mutations on cell morphology to gain insights into the molecular mechanisms. Stemming from his experimental work, Dr. Yang has also conducted theoretical investigations into the physical basis of biological rhythms; he proposed that slow diffusion of biomolecules could lead to short pauses in biochemical reactions, which in turn, produce long biological oscillations in a negative feedback loop. Dr. Yang’s group is currently investigating the functions of novel leucine-rich repeat receptor-like kinases in epidermal cell formation and proteins in meiotic checkpoint network in Arabidopsis. Dr. Yang also continues his theoretical work on various biological processes.


Jane Rosemary Allison

Affiliation: The University of Auckland, New Zealand

Biography: Jane obtained a BSc (Hons) from the University of Canterbury in 2003 and a PhD from Cambridge University in 2008, where she worked with Prof. Chris Dobson. After working as a postdoc with Prof. Wilfred van Gunsteren at ETH Zürich, she returned to New Zealand in 2012 to become a Lecturer at Massey University. She was awarded a Rutherford Discovery Fellowship in 2015, and in 2018, moved to the University of Auckland, where she is an Associate Professor and an Associate Investigator with the Maurice Wilkins Centre for Molecular Biodiscovery and the Biomolecular Interaction Centre at the University of Canterbury.


Tom Van Agtmael

Affiliation: University of Glasgow

Biography: Following his undergraduate training in Biochemistry at the University of Antwerp (Belgium), Dr. Van Agtmael obtained his PhD in molecular genetics at the Murdoch Childrens Research Institute in Melbourne (Australia). He then moved to the MRC Human Genetics Unit in Edinburgh for his post-doctoral training as an EU Marie Curie Fellow during which he identified the first vertebrate Col4a1 mutations and implicated type IV collagen in eye and kidney disease. Following a CVRI Wellcome Trust Fellowship at the University of Edinburgh, he was awarded a MRC New Investigator Research Grant to investigate the role of collagen IV in vascular biology. He then joined the University of Glasgow as a RCUK Fellow in Human Molecular Genetics where he established his research group within the Institute of Cardiovascular and Medical Sciences.


Atlanta Cook

Affiliation: University of Edinburgh

Biography: To be provided

Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal